Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome
- 837 Downloads
Osteonecrosis of the jaw (ONJ) is a well-known devastating side effect of bisphosphonate therapy for cancer. Several ONJ cases of patients using oral bisphosphonates have been reported in the literature. The present study analyzed the clinical features, predisposing factors, and treatment outcome of 11 patients with oral bisphosphonates-related ONJ.
Introduction and hypothesis
Osteonecrosis of the jaw (ONJ) is a well-known side effect of parenteral bisphosphonates therapy. Although ONJ has been reported in patients using oral bisphosphonates, documentation of this entity is sparse. It was hypothesized that the clinical features, predisposing factors, and treatment outcome of this population are different from those of oncologic patients.
This retrospective bi-central study involved 98 ONJ patients, 13 of whom were treated with oral bisphosphonates. Two patients were excluded because of previous use of intravenous bisphosphonates. The profiles of 11 patients were analyzed.
The mean duration of alendronate use before developing ONJ was 4.1 years. ONJ was triggered by dental surgery in 9 patients and by ill-fitted dentures in 2. Heavy smokers were the most recalcitrant subjects. Among the nine patients with at least 6 months of follow-up, ONJ healed completely in three, partially in four, and not at all in two.
ONJ is a rare devastating side effect of oral bisphosphonates associated with patient morbidity and high financial burden. Clinicians must be aware of this entity and inform patients of the risks of dental surgery. The synergistic effect of smoking in the pathogenesis of ONJ should be further investigated.
KeywordsAlendronate Bisphosphonate Jaws Osteomyelitis Osteonecrosis Osteoporosis
The authors would like to thank Ms. Rita Lazar and Ms. Esther Eshkol for editorial assistance.
- 10.Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334:488–493PubMedCrossRefGoogle Scholar
- 12.Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates:incidence and risk factors. J Clin Oncol 23:8580–8587PubMedCrossRefGoogle Scholar
- 13.Hoff AO, Toth B, Altundag K, Guarneri V, Nooka A, Desrouleaux K, Klein M, Adamus A, Sayegh G, Worthing A, Gagel RF, Hortobagyi GN (2005) Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. The 27th Annual Meeting of the American Society for Bone and Mineral Research; Abstract 1218Google Scholar
- 18.American Dental Association Council on Scientific Affairs (2006) Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc 137:1144–1150Google Scholar